PCV 15 - Tergene Biotech
Alternative Names: PCV 15; Pneumococcal-multivalent-conjugate-vaccine-Tergene-BiotechLatest Information Update: 28 Jun 2021
At a glance
- Originator Tergene Biotech
- Class Conjugate vaccines; Pneumococcal vaccines; Polysaccharides
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Pneumonia
Most Recent Events
- 28 Jun 2021 No recent reports of development identified for phase-I development in Pneumonia(Prevention, In adults) in India (IM, Injection)
- 31 Jan 2020 Tergene Biotech completes a phase II trial in Pneumonia (Prevention, In children) in India, before January 2020 (IM) (CTRI2019-02-017527)
- 25 Feb 2019 Phase-II clinical trials in Pneumonia (Prevention, In children) in India (IM) (CTRI2019-02-017527)